title: [Alpha blockers in the treatment of benign hyperplasia of the prostate].
authors.affiliation: Servicio de Urología, Hospital Universitario de La Princesa, Madrid.
authors.forename: F
authors.initials: F
authors.lastname: Gómez Sancha
authors.forename: M
authors.initials: M
authors.lastname: Fernández Arjona
authors.forename: F
authors.initials: F
authors.lastname: Peinado Ibarra
authors.forename: A
authors.initials: A
authors.lastname: Fernández Borrell
authors.forename: R
authors.initials: R
authors.lastname: Mínguez Martínez
authors.forename: I
authors.initials: I
authors.lastname: Pereira Sanz
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D017292:Doxazosin / Q000627:therapeutic use; D006801:Humans; D007217:Indoramin / Q000627:therapeutic use; D008297:Male; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011224:Prazosin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D011799:Quinazolines / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D000077409:Tamsulosin
chemical_list: D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; D013449:Sulfonamides; D010643:Phenoxybenzamine; D007217:Indoramin; C041226:Terazosin; C047638:alfuzosin; D000077409:Tamsulosin; D017292:Doxazosin; D011224:Prazosin